Safety and immunogenicity of a novel mammalian cell-derived recombinant hepatitis B vaccine containing Pre-S1 and Pre-S2 antigens in neonates - VBI Vaccines

Safety and immunogenicity of a novel mammalian cell-derived recombinant hepatitis B vaccine containing Pre-S1 and Pre-S2 antigens in neonates

May 1, 2001 |

Safety and immunogenicity of a novel mammalian cell-derived recombinant hepatitis B vaccine containing Pre-S1 and Pre-S2 antigens in neonates
Israel Medical Association Journal
May 2001

View More

March 13, 2023

VBI Vaccines Reports Full Year 2022 Financial Results

February 23, 2023

VBI Vaccines to Discuss Progress in Hepatitis B Portfolio in Analyst-Led Fireside Chat

February 15, 2023

VBI Vaccines Announces Presentation of Interim Phase 2 Data Evaluating Combination of VBI-2601 (BRII-179) and BRII-835 for the Treatment of Chronic Hepatitis B

December 8, 2022

VBI Vaccines Announces Health Canada Approval for PreHevbrio™ for the Prevention of Hepatitis B in Adults

Sign-up for Our Distribution List to Receive the Latest News and Updates from VBI